ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings
ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2023年年度报告（更新前） | 2024-04-25 | Chinese | |
| 关于开展外汇套期保值业务的公告 | 2024-04-25 | Chinese | |
| 睿智医药科技股份有限公司拟进行以财务报告为目的的商誉减值测试所涉及的上海睿智化学研究有限公司含商誉资产组可收回金额项目资产评估报告 | 2024-04-25 | Chinese | |
| 2023年度非经营性资金占用及其他关联资金往来情况的专项说明 | 2024-04-25 | Chinese | |
| 2023年度营业收入扣除情况专项说明 | 2024-04-25 | Chinese | |
| 未来三年（2024年-2026年）股东回报规划 | 2024-04-25 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 36041165 | 2023年年度报告（更新前） | 2024-04-25 | Chinese | ||
| 36041054 | 关于开展外汇套期保值业务的公告 | 2024-04-25 | Chinese | ||
| 36041040 | 睿智医药科技股份有限公司拟进行以财务报告为目的的商誉减值测试所涉及的上海睿智化学研究有限公司含商誉资产组可收回金额项目资产评估报告 | 2024-04-25 | Chinese | ||
| 36041016 | 2023年度非经营性资金占用及其他关联资金往来情况的专项说明 | 2024-04-25 | Chinese | ||
| 36041002 | 2023年度营业收入扣除情况专项说明 | 2024-04-25 | Chinese | ||
| 36040992 | 未来三年（2024年-2026年）股东回报规划 | 2024-04-25 | Chinese | ||
| 36040976 | 2023年环境、社会及管治（ESG）报告 | 2024-04-25 | Chinese | ||
| 36040707 | 2023年年度报告摘要（更新前） | 2024-04-25 | Chinese | ||
| 36040686 | 董事会对独董独立性评估的专项意见 | 2024-04-25 | Chinese | ||
| 36040674 | 2023年年度审计报告 | 2024-04-25 | Chinese | ||
| 36040602 | 2023年度内部控制自我评价报告 | 2024-04-25 | Chinese | ||
| 36040591 | 董事会审计委员会对会计师事务所履行监督职责情况报告 | 2024-04-25 | Chinese | ||
| 36040577 | 董事会决议公告 | 2024-04-25 | Chinese | ||
| 36040567 | 2023年度非经营性资金占用及其他关联资金往来情况汇总表 | 2024-04-25 | Chinese | ||
| 36040560 | 2023年度监事会工作报告 | 2024-04-25 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ChemPartner PharmaTech Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55161/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55161 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55161 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55161 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55161}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ChemPartner PharmaTech Co., Ltd. (id: 55161)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.